Enobosarm & Abemaciclib Combo + non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
Phase 3Terminated 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Apr 11, 2022 → Jan 9, 2024
NCT ID
NCT05065411About Enobosarm & Abemaciclib Combo + non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
Enobosarm & Abemaciclib Combo + non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant is a phase 3 stage product being developed by Veru for Metastatic Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05065411. Target conditions include Metastatic Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05065411 | Phase 3 | Terminated |
Competing Products
20 competing products in Metastatic Breast Cancer